BBC, March 23, 2026: This excellent BBC article on plastic food containers quotes NCHR’s Dr. Diana Zuckerman and other experts explaining why plastic containers are especially likely to leach dangerous chemicals when containing acidic foods like tomato sauce) or fatty foods (lasagna), or any hot food.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
As controversial decisions mount, FDA shuns public advisory meetings
STAT News, March 9, 2026: FDA is holding very few Advisory Committee meetings in 2025-26 compared to previous years. FDA says they want to avoid undue industry influence. But these meetings also provide opportunities for a diversity of opinion says NCHR’s Diana Zuckerman, who points out that FDA is avoiding meetings with experts who disagree with what the agency has already decided to do.
Read More »Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
BioSpace, March 9, 2026: In April 2026 FDA will hold its first Advisory Committee meeting on cancer drugs in 9 months — the first one in FY 2026. It will discuss 2 AstraZeneca applications, one for a new drug for HR-positive HER2-negative breast cancer and the other for Truqap to treat metastatic hormone-sensitive prostate cancer.
Read More »Prasad Out At FDA, Turning Critics’ Focus Back To Makary
Inside Health Policy, March 6, 2026: FDA’s biologics chief Vinay Prasad is leaving FDA for the second time. This time his rejection of Uniqure and other rare disease treatments angered industry and some rare disease patients, and Members of Congress. But NCHR’s Zuckerman says Prasad’s focus on evidence strengthened FDA and will be missed.
Read More »Divisive F.D.A. Vaccine Regulator Is Resigning
New York Times, March 6, 2026: FDA’s biologics chief Vinay Prasad is resigning, leaving FDA for the second time. This time his rejection of rare disease treatments angered industry, some rare disease patients, and Members of Congress. But NCHR’s Diana Zuckerman says Prasad’s focus on evidence was welcomed by researchers and advocates who were concerned about FDA’s approval of ineffective treatments.
Read More »